Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach

Journal of Cerebral Blood Flow and Metabolism

Volumn 23, Issue 8, 2003, Pages 985-996

  Pinborg, Lars H ^a   Adams, Karen H ^a   Svarer, Claus ^a   Holm, Søren ^a   Hasselbalch, Steen G ^a   Haugbøl, Steven ^a   Madsen, Jacob ^a   Knudsen, Gitte M ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Humans; PET infusion; Steady state; 18F Altanserin 5 HT2A receptors

Indexed keywords

ALTANSERIN; ALTANSERIN F 18; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; KETANSERIN; SEROTONIN RECEPTOR;

ADULT; AGED; ARTICLE; BINDING SITE; BRAIN TOMOGRAPHY; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG INFUSION; HUMAN; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; STEADY STATE; BRAIN LEVEL; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; INJECTION; MIDDLE AGED; RADIOCHEMISTRY;

ADULT; AGED; BRAIN CHEMISTRY; CEREBELLUM; FLUORINE RADIOISOTOPES; HUMANS; INJECTIONS; KETANSERIN; MIDDLE AGED; RADIOCHEMISTRY; RECEPTORS, SEROTONIN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0042735350     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WCB.0000074092.59115.23     Document Type: Article

References (35)

1. Abi-Dargham A, Laruelle M, Seibyl J, Rattner Z, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Bremner JD, Hyde TM, Charney DS (1994) SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. J Nucl Med 35:228-238
2. Biver F, Goldman S, Luxen A, Monclus M, Forestini M, Mendlewicz J, Lotstra F (1994) Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. Eur J Nucl Med 21:937-946
3. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, Herscovitch P (1993) Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13:24-42
4. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE (1994) Performance characteristics of a whole-body PET scanner. J Nucl Med 35:1398-1406
5. Eastwood SL, Burnet PW, Gittins R, Baker K, Harrison PJ (2001) Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia. Synapse 42:104-114
6. Evans AC, Marrett S, Torrescorzo J, Ku S, Collins L (1991) MRI-PET correlation in three dimensions using a volume-of-interest (VOI) atlas. J Cereb Blood Flow Metab 11:A69-A78
7. Farde L, Eriksson L, Blomquist G, Halldin C (1989) Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696-708
8. Goffinet AM, Leysen J, Labar D (1990) In vitro pharmacological profile of 3-N-(2-fluoroethyl)spiperone. J Cereb Blood Flow Metab 10:140-142
9. Ito H, Nyberg S, Halldin C, Lundkvist C, Farde L (1998) PET imaging of central 5HT2A receptors with [11C]MDL 100,907. J Nucl Med 39:208-214
10. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L (1991) Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med 32:2266-2272
11. Lewellen TK, Kohlmeyer SG, Miyaoko RS, Kaplan MS, Stearns CW, Schuber SF (1996) Investigation of the performance of the general electric ADVANCE positron emission tomograph in 3D mode. IEEE Trans Nucl Sci 43:2199-2206
12. Leysen JE (1989) Use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites. In: Drugs as Tools in Neurotransmitter Research. Neuromethods (Boulton AB, Baker GB, Jurio AV, eds), Clifton, NJ: The Human Press, pp 299-349
13. Lopresti B, Holt D, Mason NS, Huang Y, Ruszkiewicz J, Perevuznik J, Price J, Smith G, Davis J, Mathis C (1998) Characterization of the radiolabeled metabolites of [18F]altanserin: implications for kinetic modeling. In: Quantitative Functional Brain Imaging with Positron Emission Tomography (Carson RE, Daube-Witherspoon ME, Herscovitch P, eds), San Diego: Academic Press, pp 293-298
14. Meltzer CC, Smith G, Price JC, Reynolds CF III, Mathis CA, Greer P, Lopresti B, Mintun MA, Pollock BG, Ben Eliezer D, Cantwell MN, Kaye W, DeKosky ST (1998) Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res 813:167-171
15. Meuldermans W, Hendrickx J, Lauwers W, Swysen E, Hurkmans R, Knaeps F, Woestenborghs R, Heykants J (1984) Excretion and biotransformation of ketanserin after oral and intravenous administration in rats and dogs. Drug Metab Dispos 12:772-781
16. Mintun MA, Price JC, Smith GS, Lopresti B, Hartman L, Simpson N, Mathis CA (1996) Quantitative 5-HT2A receptor imaging in man using [F-18]altanserin: a new model accounting for labeled metabolites [abstract]. J Nucl Med 37:109P
17. Olsen KS, Madsen PL, Borme T, Schmidt JF (1993) The effect of ketanserin on cerebral blood flow and oxygen metabolism in healthy volunteers. Acta Neurochir (Wien) 125:83-85
18. Patlak CS, Pettigrew KD (1976) A method to obtain infusion schedules for prescribed blood concentration time courses. J Appl Physiol 40:458-463
19. Pazos A, Probst A, Palacios JM (1987) Serotonin receptors in the human brain - IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21:123-139
20. Pinborg LH, Videbaek C, Knudsen GM, Swahn CG, Halldin C, Friberg L, Paulson OB, Lassen NA (2000) Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse 36:322-329
21. Price JC, Lopresti BJ, Mason NS, Holt DP, Huang Y, Mathis CA (2001a) Analyses of [(18)F] altanserin bolus injection PET data. I: consideration of radiolabeled metabolites in baboons. Synapse 41:1-10
22. Price JC, Lopresti BJ, Meltzer CC, Smith GS, Mason NS, Huang Y, Holt DP, Gunn RN, Mathis CA (2001b) Analyses of [(18)F]altanserin bolus injection PET data. II: consideration of radiolabeled metabolites in humans. Synapse 41:11-21
23. Rosier A, Dupont P, Peuskens J, Bormans G, Vandenberghe R, Maes M, de Groot T, Schiepers C, Verbruggen A, Mortelmans L (1996) Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Res 68:11-22
24. Sadzot B, Lemaire C, Maquet P, Salmon E, Plenevaux A, Degueldre C, Hermanne JP, Guillaume M, Cantineau R, Comar D (1995) Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls. J Cereb Blood Flow Metab 15:787-797
25. Schotte A, Maloteaux JM, Laduron PM (1983) Characterization and regional distribution of serotonin S2-receptors in human brain. Brain Res 276:231-235
26. Sheline YI, Mintun MA, Moerlein SM, Snyder AZ (2002) Greater loss of 5-HT(2A) receptors in midlife than in late life. Am J Psychiatry 159:430-435
27. Smith GS, Price JC, Lopresti BJ, Huang Y, Simpson N, Holt D, Mason NS, Meltzer CC, Sweet RA, Nichols T, Sashin D, Mathis CA (1998) Test-retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain. Synapse 30:380-392
28. Soares JC, van Dyck CH, Tan P, Zoghbi SS, Garg P, Soufer R, Baldwin RM, Fujita M, Staley JK, Fu X, Amici L, Seibyl J, Innis RB (2001) Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin. Psychiatry Res 106:81-93
29. Staley JK, van Dyck CH, Tan PZ, Al Tikriti M, Ramsby Q, Klump H, Ng C, Garg P, Soufer R, Baldwin RM, Innis RB (2001) Comparison of [(18)F]altanserin and [(18)F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: pharmacological studies. Nucl Med Biol 28:271-279
30. Tan PZ, Baldwin RM, van Dyck CH, Al Tikriti M, Roth B, Khan N, Charney DS, Innis RB (1999) Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. Nucl Med Biol 26:601-608
31. van Dyck CH, Soares JC, Tan P, Staley JK, Baldwin RM, Amici LA, Fu X, Garg PK, Seibyl JP, Charney DS, Innis RB (2000a) Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. Nucl Med Biol 27:715-722
32. van Dyck CH, Tan PZ, Baldwin RM, Amici LA, Garg PK, Ng CK, Soufer R, Charney DS, Innis RB (2000b) PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin. J Nucl Med 41:234-241
33. Watabe H, Channing MA, Der MG, Adams HR, Jagoda E, Herscovitch P, Eckelman WC, Carson RE (2000) Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907. J Cereb Blood Flow Metab 20:899-909
34. Willendrup P, Svarer C, Hasselbalch SG, Knudsen GM (2002) Precision of coregistration techniques for F18-altanserin PET images [abstract]. NeuroImage 16:S85
35. Woods RP, Cherry SR, Mazziotta JC (1992) Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 16:620-s633